Option Chain

Vera Therapeutics Inc

VERANASDAQ · USD

31.67USD+0.96 (+3.13%)

129

Vera Therapeutics Inc (VERA) Option Chain

Vera Therapeutics Inc trades at $31.67, up 3.13%, with an IV Rank of 51.98%. This is average versus the past year, and the company carries a market cap of $2,213M in the Biotechnology industry. On the Nov 20, 2026 chain, the at the money $30.00 strike shows calls at $1.45 / $3.50 and puts at $1.45 / $2.60, both carrying about $1.41 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $40.00 calls, at 251 contracts, and the $30.00 puts, at 8, as of Nov 3, 2026.

Tracking the VERA option chain helps you see every strike and expiry on Vera Therapeutics Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of VERA options activity at a glance. Use our scanner to monitor the VERA option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For VERA stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where VERA options are being actively traded, and where they are not.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc.

CALLs									PUTs
Prob. OTM %	Open Interest	Volume	Extrinsic Value	Intrinsic Value	Bid	Ask	Strike	Moneyness %	Bid	Ask	Intrinsic Value	Extrinsic Value	Volume	Open Interest	Prob. OTM %
5.08	0	0	-0.62	9.17	6.30	10.80	22.50	-26.73	—	2.80	0.00	2.80	0	0	94.92
14.56	242	0	-0.57	6.67	3.90	8.30	25.00	-18.59	—	1.00	0.00	1.00	0	25	85.44
48.06	171	0	0.80	1.67	1.45	3.50	30.00	-2.31	1.45	2.60	0.00	2.03	8	78	51.94
78.89	4,372	32	0.50	0.00	0.20	0.80	35.00	+13.97	3.40	7.10	3.33	1.92	0	2	21.11
93.82	193	251	0.30	0.00	—	0.30	40.00	+30.25	7.10	11.90	8.33	1.17	0	0	6.18

As of Nov 3, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

IndustryBiotechnology
SectorHealthcare
IV Rank51.98% Moderate
Market cap (M$)2,213
52 weeks high-45.21%
52 weeks low33.23%
Analyst recommendationStrong Buy
1.29
Target price$73.79
134.29% above the current stock price
Dividend—
Payout ratio—
Earnings date2026-11-05
P/E—
Future P/E—
EPS (ttm)-5.87
EPS growth next 5 years49.91%

As of Nov 3, 2026

Browse all Option Chain tickers